1. Home
  2. MDWD vs SNFCA Comparison

MDWD vs SNFCA Comparison

Compare MDWD & SNFCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • SNFCA
  • Stock Information
  • Founded
  • MDWD 2000
  • SNFCA 1965
  • Country
  • MDWD Israel
  • SNFCA United States
  • Employees
  • MDWD N/A
  • SNFCA N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • SNFCA Finance: Consumer Services
  • Sector
  • MDWD Health Care
  • SNFCA Finance
  • Exchange
  • MDWD Nasdaq
  • SNFCA Nasdaq
  • Market Cap
  • MDWD 208.2M
  • SNFCA 236.8M
  • IPO Year
  • MDWD 2014
  • SNFCA N/A
  • Fundamental
  • Price
  • MDWD $17.14
  • SNFCA $8.61
  • Analyst Decision
  • MDWD Strong Buy
  • SNFCA
  • Analyst Count
  • MDWD 2
  • SNFCA 0
  • Target Price
  • MDWD $35.00
  • SNFCA N/A
  • AVG Volume (30 Days)
  • MDWD 154.9K
  • SNFCA 36.0K
  • Earning Date
  • MDWD 08-14-2025
  • SNFCA 11-13-2025
  • Dividend Yield
  • MDWD N/A
  • SNFCA N/A
  • EPS Growth
  • MDWD N/A
  • SNFCA 2.26
  • EPS
  • MDWD N/A
  • SNFCA 0.89
  • Revenue
  • MDWD $19,858,000.00
  • SNFCA $339,824,006.00
  • Revenue This Year
  • MDWD $20.37
  • SNFCA N/A
  • Revenue Next Year
  • MDWD $25.91
  • SNFCA N/A
  • P/E Ratio
  • MDWD N/A
  • SNFCA $9.79
  • Revenue Growth
  • MDWD N/A
  • SNFCA 5.49
  • 52 Week Low
  • MDWD $14.14
  • SNFCA $7.32
  • 52 Week High
  • MDWD $22.51
  • SNFCA $12.94
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 45.84
  • SNFCA 47.95
  • Support Level
  • MDWD $16.08
  • SNFCA $8.38
  • Resistance Level
  • MDWD $20.30
  • SNFCA $8.87
  • Average True Range (ATR)
  • MDWD 0.93
  • SNFCA 0.27
  • MACD
  • MDWD 0.20
  • SNFCA 0.01
  • Stochastic Oscillator
  • MDWD 25.12
  • SNFCA 45.00

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About SNFCA Security National Financial Corporation

Security National Financial Corp is engaged in the life insurance, cemetery and mortuary, and mortgage loan businesses. The life insurance segment is engaged in the business of selling and servicing selected lines of life insurance, annuity products, and accident and health insurance. Its cemetery and mortuary segment consists of approximately seven mortuaries and five cemeteries in the state of Utah and a cemetery in the state of California. The mortgage loan segment originates and underwrites or otherwise purchases residential and commercial loans for new construction, existing homes, and real estate projects. Geographically, all the business activity is functioned through the region of the USA and it derives the majority of revenue from Mortgage segment.

Share on Social Networks: